MLLT3 and acute myeloid leukemia: In the context of MLL-AF9 AML, treatment with LSD1 inhibitors induces gains in chromatin accessibility with enrichment of myeloid TF motifs for PU.1, C/EBPα-b, and RUNX1 (29).